The worldwide market for diabetes treatments is projected to reach $163.79 billion by 2034, driven by demographic shifts and innovative drug classes that are transforming care beyond glucose management.
The global market for diabetes medicines is expected to reach $163.79 billion by 2034, according to Polaris Market Research, as the burden of type 2 diabetes continues to rise worldwide. The report links that growth to ageing populations, more sedentary habits and higher obesity rates, all of which are increasing demand for long-term treatment.
Polaris said the market is also being reshaped by newer drug classes, particularly GLP-1 receptor agonists and SGLT-2 inhibitors. These medicines have broadened the focus of diabetes care beyond blood sugar control alone, with clinicians and drugmakers paying closer attention to cardiovascular and kidney complications that often accompany the disease.
The report said type 2 diabetes accounts for the larger share of revenue, helped by advances in insulin therapies and delivery systems. Oral medicines remain the most widely used form of treatment, led by metformin and SGLT-2 inhibitors, while insulin still represents the biggest drug class overall, especially in type 1 diabetes. SGLT-2 inhibitors are forecast to be the fastest-growing category because of their heart and kidney benefits.
North America currently holds the largest share of the market, supported by high diabetes prevalence and a well-established healthcare system. Asia-Pacific, however, is expected to grow the fastest as case numbers rise and access to care improves. That regional split reflects a broader shift in the diabetes landscape, with pharmaceutical companies racing to develop next-generation therapies and expand their presence in a market that is becoming more competitive by the year.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
